Cumulative results for 2Q FY2026 show sales revenue up +19.7% YoY and operating income up +34.4% YoY. No revision to full-year forecast. Growth driven by key products ENHERTU and Tarlatamab. Reviewed and corrected CMO loss compensation items. Strengthening financial soundness and promoting operational excellence.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4568","jir_company_name":"Daiichi Sankyo Company, Limited","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-10-30","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/10\/4568-20261030-03.pdf","jir_short_summary":"Cumulative results for 2Q FY2026 show sales revenue up +19.7% YoY and operating income up +34.4% YoY. No revision to full-year forecast. Growth driven by key products ENHERTU and Tarlatamab. Reviewed and corrected CMO loss compensation items. Strengthening financial soundness and promoting operational excellence.","jir_summary":"### Overview of Performance\nCumulative results through 2Q FY2026 showed a substantial increase in sales revenue versus the prior period, with improved cost ratios and foreign exchange effects leading to a significant rise in operating income. Supported by growth of core products ENHERTU\u00ae and Tarlatamab\u00ae, sales revenue has exceeded one trillion yen by the second quarter. The company targets record-high full-year sales revenue.\n\n### Outlook and Financial Measures\nConsolidated earnings forecasts for FY2026 remain unchanged from the July announcement. Measures to enhance the reliability of financial reporting include additional reversals and corrective actions related to provisions for CMO loss compensation. The company aims to balance profit contribution and future growth investment through the promotion of operational excellence.","jir_financial_highlights":"Sales Revenue: 9,754 (Year-over-Year +19.7%)\nOperating Income: 1,442 (Year-over-Year +34.4%)\nNet Income Attributable to Owners of Parent: 1,308 (Year-over-Year +13.3%)\nForeign Exchange Impact: USD\/JPY 146.04 \u2192 159.37, EUR\/JPY 168.06 \u2192 184.35 (Explained as a factor affecting results)","jir_category":"","jir_hashtags":"#DaiichiSankyo, #Earnings, #BusinessUpdate, #OperationalExcellence","jir_key_figures":"Sales Revenue: 9,754 hundred million yen (Year-over-Year +19.7%)\nOperating Income: 1,442 hundred million yen (Year-over-Year +34.4%)\nNet Income Attributable to Owners of Parent: 1,308 hundred million yen (Year-over-Year +13.3%)","jir_meta_title":"Daiichi Sankyo Company, Limited - 2Q FY2026 Financial Presentation | Revenue, Profit Trends and Outlook","jir_meta_description":"Summary of Daiichi Sankyo's 2Q FY2026 results: sales +19.7% YoY, operating income +34.4% YoY. Covers outlook, treatment of CMO compensation, improvements to financial reporting reliability, key product trends and mid-term plan highlights.","jir_og_title":"Daiichi Sankyo | Financial Presentation: 2Q Performance and Outlook","jir_og_description":"Daiichi Sankyo's 2Q FY2026 results showed substantial increases in revenue and profits. Summary of core product growth, financial reforms and outlook.","jir_og_image_url":"\/assets\/og\/company-financial_summary.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Sales Revenue Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"FY2025 Q2\\\",\\\"FY2026 Q2\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Sales Revenue\\\",\\\"data\\\":[9754,11672]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Operating Income Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"FY2025 Q2\\\",\\\"FY2026 Q2\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Income\\\",\\\"data\\\":[1442,1938]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Segment Revenue Breakdown\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Oncology\\\",\\\"ASCA\\\",\\\"Japan Business\\\"],\\\"datasets\\\":[{\\\"data\\\":[? , ?, ?]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"margin_analysis\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Core Operating Margin\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"FY2025 Q2\\\",\\\"FY2026 Q2\\\"],\\\"datasets\\\":[{\\\"data\\\":[? , ?]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"guidance_comparison\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Forecast vs. Actual Comparison\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"July Publication\\\",\\\"October Publication\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Sales Forecast\\\",\\\"data\\\":[9153,9153]}]},\\\"options\\\":{}}\"}]","ir_related_company":6853,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-137318","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n